Tatva Chintan Pharma Chem Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Tatva Chintan Pharma Chem's earnings have been declining at an average annual rate of -20.7%, while the Chemicals industry saw earnings growing at 15.6% annually. Revenues have been declining at an average rate of 2.8% per year. Tatva Chintan Pharma Chem's return on equity is 2.4%, and it has net margins of 4.7%.
Belangrijke informatie
-20.7%
Groei van de winst
-23.5%
Groei van de winst per aandeel
| Chemicals Groei van de industrie | 17.7% |
| Inkomstengroei | -2.8% |
| Rendement op eigen vermogen | 2.4% |
| Nettomarge | 4.7% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Weak Statutory Earnings May Not Tell The Whole Story For Tatva Chintan Pharma Chem (NSE:TATVA)
May 11
Recent updates
Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Price In Tune With Revenues
Sep 26Tatva Chintan Pharma Chem (NSE:TATVA) Has Affirmed Its Dividend Of ₹2.00
Aug 29Earnings Report: Tatva Chintan Pharma Chem Limited Missed Revenue Estimates By 33%
Jul 27Weak Statutory Earnings May Not Tell The Whole Story For Tatva Chintan Pharma Chem (NSE:TATVA)
May 11Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Share Price Matching Investor Opinion
Apr 04These Analysts Just Made A Notable Downgrade To Their Tatva Chintan Pharma Chem Limited (NSE:TATVA) EPS Forecasts
Jan 26Tatva Chintan Pharma Chem Limited (NSE:TATVA) Analysts Are Reducing Their Forecasts For This Year
May 10Tatva Chintan Pharma Chem Limited Just Missed Revenue By 15%: Here's What Analysts Think Will Happen Next
Jul 28Getting In Cheap On Tatva Chintan Pharma Chem Limited (NSE:TATVA) Is Unlikely
Jun 17Investors Shouldn't Be Too Comfortable With Tatva Chintan Pharma Chem's (NSE:TATVA) Robust Earnings
May 03Are Investors Undervaluing Tatva Chintan Pharma Chem Limited (NSE:TATVA) By 45%?
Dec 06Opbrengsten en kosten
Hoe Tatva Chintan Pharma Chem geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 3,714 | 176 | 548 | 0 |
| 30 Jun 24 | 3,846 | 261 | 552 | 0 |
| 31 Mar 24 | 3,935 | 304 | 563 | 0 |
| 31 Dec 23 | 4,198 | 377 | 526 | 0 |
| 30 Sep 23 | 4,562 | 459 | 483 | 0 |
| 30 Jun 23 | 4,496 | 452 | 416 | 0 |
| 31 Mar 23 | 4,236 | 455 | 431 | 0 |
| 31 Dec 22 | 3,976 | 460 | 377 | 0 |
| 30 Sep 22 | 3,817 | 572 | 353 | 0 |
| 30 Jun 22 | 4,152 | 825 | 324 | 0 |
| 31 Mar 22 | 4,336 | 959 | 320 | 0 |
| 31 Dec 21 | 4,438 | 995 | 311 | 0 |
| 30 Sep 21 | 4,192 | 976 | 300 | 0 |
| 30 Jun 21 | 3,557 | 687 | 279 | 0 |
| 31 Mar 21 | 3,004 | 523 | 253 | 0 |
| 31 Mar 20 | 2,632 | 378 | 217 | 0 |
| 31 Mar 19 | 2,063 | 205 | 174 | 0 |
| 31 Mar 18 | 1,358 | 123 | 131 | 0 |
Kwaliteitswinsten: TATVA has high quality earnings.
Groeiende winstmarge: TATVA's current net profit margins (4.7%) are lower than last year (10.1%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: TATVA's earnings have declined by 20.7% per year over the past 5 years.
Versnelling van de groei: TATVA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: TATVA had negative earnings growth (-61.6%) over the past year, making it difficult to compare to the Chemicals industry average (10.4%).
Rendement op eigen vermogen
Hoge ROE: TATVA's Return on Equity (2.4%) is considered low.